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Protein ubiquitination plays an important role in reg-
ulating the abundance and conformation of a broad
range of eukaryotic proteins. This process involves a
cascade of enzymes including ubiquitin-activating en-
zymes (E1), ubiquitin-conjugating enzymes (E2), and
ubiquitin ligases (E3). E1 and E2 represent two families
of structurally related proteins and are relatively well
characterized. In contrast, the nature and mechanism of
E3, proposed to contain activities in catalyzing isopep-
tide bond formation (ubiquitin ligation) and substrate
targeting, remains inadequately understood. Two major
families of E3 ubiquitin ligases, the HECT (for homolo-
gous to E6-AP C terminus) family and the RING family,
have been identified that utilize distinct mechanisms in
promoting isopeptide bond formation. Here, we showed
that purified RING finger domain of ROC1, an essential
subunit of SKP1-cullin/CDC53-F box protein ubiquitin
ligases, was sufficient to activate UBCH5c to synthesize
polyubiquitin chains. The sequence flanking the RING
finger in ROC1 did not contribute to UBCH5c activation,
but was required for binding with CUL1. We demon-
strated that all cullins, through their binding with ROC
proteins, constituted active ubiquitin ligases, suggest-
ing the existence in vivo of a large number of cullin-
RING ubiquitin ligases. These results are consistent
with the notion that the RING finger domains allosteri-
cally activate E2. We suggest that RING-E2, rather than
cullin-RING, constitutes the catalytic core of the ubiq-
uitin ligase and that one major function of the cullin
subunit is to assemble the RING-E2 catalytic core and
substrates together.
Through a cascade of enzymes involving ubiquitin activating
(Uba or E1),1 conjugating (Ubc or E2), and ligating (E3) activ-
ities, the protein ubiquitination pathway catalyzes the forma-
tion of polyubiquitin chains onto substrate proteins via isopep-
tide bonds. Polyubiquitinated substrates are then rapidly
delivered to and degraded by the 26 S proteasome (1, 2). Both
E1 and E2 represent structurally related proteins and are
relatively well characterized. Five E1s have been described for
activating ubiquitin or ubiquitin-like modifiers (3): monomeric
E1s Uba1, Apg7, and Uba4 that activate ubiquitin, Apg12, and
Urm1, respectively; and two heterodimeric E1-like complexes
Uba3-Ula1 and Uba2-Aos1, which activate Rub1/Nedd8 and
SUMO-1, respectively. E2 ubiquitin-conjugating enzymes con-
tain a conserved 150-amino acid catalytic core and are pres-
ent in the eukaryotic genome as a multigene family (13 in
budding yeast, 29 in fruit fly, and at least 33 in human ge-
nomes). The E3 ubiquitin ligases, on the other hand, have been
defined more ambiguously and operatively as an activity in-
volved in both catalyzing isopeptide bond formation (ubiquitin
ligation) and recruiting substrate. Currently, two major fami-
lies of E3 ligases have been described. The homologous to
E6-AP C terminus (HECT) family of E3s was discovered in the
studies of ubiquitin-mediated degradation of tumor suppressor
p53 in cells expressing papilloma viral oncoprotein E6 (4). E6
associates with a cellular protein, E6AP, to promote p53 deg-
radation (5, 6). A domain of 350 residues located at the C
terminus of E6AP contains an active cysteine residue that can
form thioester linkages with ubiquitin and whose mutation
abolished the ligase activity of E6AP (4, 7). A large number of
cellular proteins with otherwise diverse structures contain a
domain homologous to E6-AP C terminus (2, 8). One biochem-
ical mechanism underlying the physiological functions of these
HECT domain-containing proteins is believed to be protein
ubiquitination.
The second family of E3s contains a RING finger domain or
subunit essential for their ubiquitin ligase activity (8–11). The
RING finger motif was initially defined a decade ago as a novel
cysteine-rich sequence present in several otherwise unrelated
proteins (12). There exist a large number of RING finger-
containing proteins in all eukaryotes (more than 350 in human
genome), implicating a broad involvement of RING-dependent
ubiquitination. The RING finger comprises eight cysteine and
histidine residues that bind two atoms of zinc to form one
unique three-dimensional structure referred to as the cross-
brace rather than two separate mini-domains (13). Both the
length and sequence between these eight conserved Cys and
His residues vary significantly among different RING fingers.
Based on the arrangement of Cys and His residues, RING
fingers can be categorized into three subclasses: C3H2C3 (or
RING-H2), C3HC4 (or RING-HC), and infrequently C2H2C4.
Despite its presence in a wide range of proteins involved in
various important cellular processes, the biochemical function
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of the RING finger was unknown until the relatively recent
discovery of its role in protein ubiquitination. Of a half-dozen
well characterized RING finger proteins, investigations of
ROC1 and APC11 have contributed significantly to our real-
ization of RING finger domain mediated ubiquitination. APC11
is a subunit of the anaphase-promoting complex (APC or cyclo-
some) that is required for both entry into anaphase as well as
exit from mitosis (14, 15). ROC1 (also known as Rbx1 and Hrt1)
is an essential subunit of SKP1-cullin 1/CDC53-F box protein
(SCF) complexes that function in regulating G1 cell cycle con-
trol and signal transduction (16–20). Unlike most other RING
finger-containing proteins, both ROC1 (108 residues) and
APC11 (84 residues) are small proteins with the RING finger
taking up most of the coding capacity. Various mutational
analyses have demonstrated the requirement of each of the
eight conserved Cys or His residues, and thus the integrity of
RING finger, for the ubiquitin ligase activity.
A third emerging family of E3s contains a so-called U box, a
domain of  100 amino acid residues present in diverse pro-
teins from all eukaryotic organisms. The prototype of U box
proteins, yeast UFD2, was identified by its activity to collabo-
rate with E1, E2, and a HECT domain protein UFD4 for an
efficient synthesis of polyubiquitin chains (21). At least six U
box proteins have been found to mediate polyubiquitination in
the presence of E1 and E2, but absence of E3 (22). Despite
lacking signature Cys and His residues in the U box, a com-
puter-assisted data base search and three-dimensional struc-
tural threading revealed a similarity between the RING finger
domain and the U box from various proteins, including UFD2
(23). These observations suggest that U boxes more likely rep-
resent a modified version of the RING finger that probably acts
as a E3 via a mechanism similar to that of the RING finger
family, rather than constitute a distinct fourth activity on the
E1-E2-E3 ubiquitination pathway.
The exact biochemical mechanism underlying the function of
RING fingers in protein ubiquitination remains incompletely
understood. In vivo, the function of ROC1 and APC11 are
dependent on their interactions with CUL1 and cullin-related
APC2, respectively. ROC1 function has been linked to stabilize
or bridge the interaction of E2 with cullins (18, 19), to promote
cullin nuclear accumulation (24), and to facilitate covalent
modification of cullins by a ubiquitin-like protein, NEDD8/
Rub1 (16, 24). Surprisingly, APC11 alone, in the absence of
cullin-like APC2, can interact with E2-UBC4 and is sufficient
to promote E1- and E2-dependent polyubiquitin chain forma-
tion on protein substrates (25, 26), and our confirmatory re-
sults using human APC11 and UbcH5c). This finding raises the
question on the role of RING fingers in E2 activation and
substrate recognition. We report that ROC1 contains two do-
mains, the C-terminally located RING finger that alone is
sufficient to activate UBC5 and an N-terminal domain required
for binding with CUL1. We demonstrate that cullins, through
their binding with a ROC protein and the autonomous allo-
steric activation of E2 by the ROC RING finger, could assemble
more than a dozen distinct ubiquitin ligases.
EXPERIMENTAL PROCEDURES
Plasmids and Purification of Recombinant Proteins—Full-length
mammalian cullins, ROC1, ROC2, APC11, APC2, SKP1, and SKP2
expression plasmids were described in Refs. 17 and 27. -TrCP clone
was a gift from Dr. Yinon Ben-Neriah. ROC1 mutants were generated
by site-directed mutagenesis using the QuikChange kit (Stratagene)
and verified by DNA sequencing. Different E2s were amplified from a
HeLa cDNA library by PCR and inserted into a T7 bacterial expression
vector fused in-frame with a hexahistidine tag. Sequences for each
ROC1 mutant and amplified E2 were verified by direct DNA sequenc-
ing. Purified rabbit E1 ubiquitin-activating enzyme (Affiniti, United
Kingdom) and ubiquitin (Sigma) were purchased commercially. Hexa-
histidine-tagged ubiquitin (containing protein kinase C phosphoryla-
tion site) and E2 proteins were expressed in bacteria using the pET-
3E-6xHis vector with isopropyl-1-thio--D-galactopyranoside induction,
purified using nickel beads (Qiagen) according to the manufacturer’s
instructions, and stored with 10% glycerol at 80 °C. Hexahistidine-
tagged mCDC34 was expressed using a baculovirus and purified from
Sf9 insect cells. The concentrations of all the purified proteins were
determined by Coomassie Brilliant Blue staining prior to the ubiquiti-
nation assay. GST-tagged ROC1 and ROC2 were expressed in BL21
(DE3) bacteria using the pGEX vector with isopropyl-1-thio--D-galac-
topyranoside induction and purified using glutathione-agarose (Sigma).
Cell Culture and Immunological Techniques—293T cells were cul-
tured in Dulbecco’s modified Eagle’s medium, supplemented with 10%
fetal bovine serum in a 37 °C incubator with 5% CO2. Cell transfections
were carried out using calcium-phosphate buffer. For each transfection
15 or 5 g of total plasmid DNA were used per 100- or 60-mm dish,
respectively. Procedures for immunoprecipitation and immunoblotting
have been described previously (28) with modification of the lysis buffer
(15 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.5% Nonidet P-40, 1 mM phen-
ylmethylsulfonyl fluoride, 1 mM DTT, 1 mM Na3VO4, 2 g/ml aprotinin,
2 g/ml leupeptin, 10 g/ml trypsin inhibitor, and 150 g/ml benzami-
dine). Rabbit polyclonal anti-cullin 1 (27), anti-ROC1 (17), and anti-
APC11 (29) antibodies have been described previously.
Ubiquitin Ligase Activity Assay—The procedure for ubiquitin label-
ing was described in Refs. 17 and 20. ROC and cullin immunocomplexes
were precipitated from untransfected 293T cells with affinity-purified
anti-ROC1 (1.5 g) or anti-APC11 (3 g) antibody, or from transfected
cells with 3 g of affinity-purified anti-CUL1, anti-HA, or anti-Myc
antibody. For substrate-free ubiquitination assays, individual immuno-
complexes were immobilized on protein A-agarose beads, washed three
times with Nonidet P-40 cell lysis buffer, and washed twice with a
buffer containing 25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA,
0.01% Nonidet P-40, and 10% glycerol. Washed immunocomplexes were
added to a ubiquitin ligation reaction (final volume 30 l) containing 50
mM Tris-HCl, pH 7.4, 5 mM MgCl2, 2 mM NaF, 10 nM okadaic acid, 2 mM
ATP, 0.6 mM DTT, 0.75 g of [32P]ubiquitin, 60 ng of E1, and 300 ng of
E2. Reactions were incubated at 37 °C for 30 min, terminated by boiling
for 5 min with SDS-sample buffer containing 0.1 M DTT, and resolved
by SDS-PAGE followed by autoradiography to visualize ubiquitin
ladders.
RESULTS
ROC1 and APC11 Interact with Both CDC34 and UBCH5c—
Discovery of ROC1 and ROC2 proteins, their combinatorial
interactions with different cullins, and the function of cullin-
ROC complexes in ubiquitination of various substrates raises
issues on the role of ROC and cullin protein in ubiquitin liga-
tion. Although only one E1 gene exists for activating ubiquitin,
there are multiple E2s involved in ubiquitin conjugation (e.g.
13 in yeast) and an unknown number of E3s. Specific sub-
strates may be selectively ubiquitinated by different E3s, and
different E3s may preferentially interact with different E2s.
This generates a potentially enormous complexity when assay-
ing for in vitro ubiquitination of a specific substrate. Therefore,
before testing in vitro ubiquitination of specific substrates, we
first determined the interactions between different E2s and
ROC1- and APC11-associated ligases in the absence of a sub-
strate. This was made possible by the finding that the ROC1-
CUL1 and APC11-APC2 complexes can promote ubiquitin-
ubiquitin ligation in the absence of exogenously added
substrate (20, 29). Ubc3/CDC34 and UbcH5c were expressed
and purified from insect cell or bacteria, respectively, to near
homogeneity (Fig. 1A), and incubated with either the ROC1 or
the APC11 immunocomplex in the presence of purified E1 and
32P-labeled ubiquitin. These two immunocomplexes represent
a number of distinct ubiquitin ligases; the anti-ROC1 immuno-
complex contains at least four different ROC1-cullin ligases
(ROC1-CUL1, ROC1-CUL2, ROC1-CUL3, and ROC1-CUL4A),
and the APC11 immunocomplex contains APC2 (29). Ubiquitin
ligation was determined by incorporation of 32P-labeled ubiq-
uitin into a high molecular weight smear characteristic of an
incremental ubiquitin ladder. Incubation of ROC1 immuno-
complexes with CDC34 and UbcH5c resulted in the formation
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of a polyubiquitin chain (Fig. 1B). Distinctly, the APC11 im-
munocomplex promoted polyubiquitination when incubated
with UbcH5c but exhibited very little polyubiquitination activ-
ity over the background when incubated with CDC34. This is
consistent with the observation that CDC34 functions during
the G1 phase of the cell cycle, whereas the APC is most active
during mitosis, an activity that is not affected by CDC34 mu-
tation. UbcH5c shares 97% identity with Ubc4, an E2 that
mediates APC-dependent cyclin B1 ubiquitination (30). Taken
together, these results suggest that, as determined by the
substrate-independent in vitro ubiquitination assay, ROC1-
associated ligases can utilize CDC34 and UbcH5c, and the
APC11-APC2 ligase can use UbcH5c.
Activation of UbcH5 by Purified Recombinant ROC1—
Prompted by the finding that purified recombinant APC11
alone is sufficient to activate Hbc4 (25, 26), we tested whether
purified recombinant ROC1 and ROC2 can activate UbcH5 and
CDC34 in vitro in the absence of their cullin partners. GST-
ROC1 fusion protein was expressed in bacteria and purified to
near homogeneity (Fig. 2A) and incubated with purified
UbcH5c in the presence of E1 and 32P-labeled ubiquitin. As
shown in Fig. 2B, recombinant GST-ROC1, but not control GST
protein (lane 3), was capable of activating UbcH5c to synthe-
size polyubiquitin chains in a dose-dependent manner (lanes
4–6) to an efficiency similar to that observed with ROC1-CUL1
complexes derived from transfected 293T cells (lane 2). Omit-
ting E1 (lane 7) abolished polyubiquitin chain formation,
indicating that ROC1-mediated UbcH5c activation is
E1-dependent.
The RING Finger Domain of ROC1 Is Sufficient to Activate
UbcH5—We next determined the sequence within ROC1 that
is necessary for activating UbcH5c. The human ROC1 protein
contains 108 amino acid residues. The H2-RING finger occu-
pies the C-terminal half of the protein and many mutations
within the RING finger abolish its ligase activity. The function
of the N-terminal half of ROC1 has not been determined. We
generated two deletion mutants, ROC1N23 and ROC1N41,
which removed the N-terminal 23 and 41 residues from ROC1,
respectively (Fig. 3A), and determined their effect on binding
with CUL1 in vivo and activating UbcH5c in vitro. Both dele-
tion mutants, as well as a deletion mutant that removed the
C-terminal 14 residues (ROC1C14), and two double point mu-
tants within the RING finger, were fused in-frame with an HA
epitope tag and inserted into a cytomegalovirus-based mam-
malian expression vector. Individual plasmids expressing wild
type ROC1 and individual ROC1 mutants were co-transfected
with T7 epitope-tagged CUL1 into 293T cells. ROC1-CUL1
complex formation was examined by coupled immunoprecipi-
tation and immunoblotting (Fig. 3B, IP, WB). Both N23 and
N41 deletions severely reduced the association of ROC1 with
CUL1 (lanes 6 and 7). In contrast, deletion of the C-terminal 14
residues and two double mutations within the RING finger did
not detectably affect ROC1-CUL1 binding. Taken together,
these results indicate that the N-terminal portion of ROC1 is
required for the association with CUL1.
To determine whether the N-terminal domain of ROC1 is
required for E2 activation, we expressed and purified GST
fusion proteins containing these mutations. Both purified GST-
ROC1N23 and GST-ROC1N41 activated UbcH5c in vitro at an
efficiency similar to that reached by the wild type GST-ROC1
protein. In contrast, deletion of the C-terminal 14 residues or
several double mutations within the RING finger completely
abolished the E2 activation function of ROC1 (Fig. 3C). These
results demonstrate that the RING domain alone is sufficient
FIG. 1. Activation of E2s by ROC1 and APC11 immunocom-
plexes. A, His6-tagged CDC34 was purified from Sf9 insect cells and
UbcH5c was purified from bacteria using nickel beads. Each protein (2
g) was resolved by SDS-PAGE followed by Coomassie Blue staining. B,
immunoprecipitated ROC1 and APC11 complexes from 293T cells were
incubated with the same amount of E1, 32P-labeled ubiquitin, and 300
ng of CDC34 or UbcH5c. After incubating at 37 °C for 30 min, the
reaction was terminated by adding sample buffer containing SDS (2%)
and DTT (0.1 M), boiled for 5 min, and resolved by SDS-PAGE followed
by autoradiography.
FIG. 2. In vitro activation of UbcH5c by purified recombinant
ROC1. A, full-length human ROC1 and ROC2 were fused with GST
moiety, expressed in bacteria, and purified using glutathione-agarose.
Each purified protein was resolved by SDS-PAGE followed by Coomas-
sie Blue staining. B, immunoprecipitated CUL1-ROC1 complexes, pu-
rified GST, or GST-ROC1 fusion proteins were incubated with the same
amount of E1, 32P-labeled ubiquitin, and 300 ng of purified UbcH5c.
After incubating at 37 °C for 30 min, the reaction was terminated by
adding sample buffer containing SDS (2%) and DTT (0.1 M), boiled for 5
min, and resolved by SDS-PAGE followed by autoradiography.
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to activate UbcH5c and does not require the N-terminal
sequence.
That the ROC1 alone is sufficient to activate an E2 to syn-
thesize polyubiquitin chain formation in the absence of other
ROC1-associated co-factors led us to test whether ROC1 can be
crafted onto a heterologous protein and still retain its function
to activate an E2. The entire sequence of ROC1 was fused
in-frame with CDK4 and a Myc epitope tag. Myc-CDK4-ROC1
fusion protein was immunoprecipitated from transiently trans-
fected 293T cells using anti-Myc antibody and incubated with
32P-labeled ubiquitin in the presence of E1 and UbcH5c. Myc-
CDK4-ROC1 exhibited a high level of activity similar to that
seen with Myc-ROC1 to activate UbcH5c to synthesize polyu-
biquitin chains (Fig. 3D, lane 3). Introduction of a double point
mutation, C75A/H77A, into the RING finger substantially re-
duced the polyubiquitin chain formation activity (lane 4). This
result further supports the autonomous function of ROC1 in
activating E2 and suggests the possibility of engineering RING
finger-based chimerical ubiquitin ligases for targeting the ubiq-
uitination and degradation of selected proteins.
ROC1 Alone Cannot Activate CDC34—We next determined
whether purified recombinant ROC1 could activate other E2
CDC34. Purified recombinant ROC1, unlike ROC1 immuno-
precipitated from mammalian cells, was unable to activate
CDC34 (Fig. 4). The simplest explanation is that different E2s
may interact distinctly with E3s and that ROC1 immunocom-
plexes derived from mammalian cells contain an additional
factor(s) that is necessary for ROC1 to activate CDC34. One
candidate factor is cullin proteins. Consistent with a require-
ment of cullins in ROC1-mediated CDC34 activation, HA-
ROC1 immunocomplexes derived from cells co-transfected with
CUL1 are more potent in activating CDC34 than those derived
from cells singly transfected with ROC1 (Fig. 4B, compare lane
3 with lane 2). Likewise, anti-HA immunocomplexes derived
from cells co-transfected with CUL1 and CUL1-binding defi-
cient HA-ROC1N23 did not appreciably activate CDC34 (lane
4).
Activation of UbcH5c by Purified Recombinant ROC2—
ROC1 has a closely related homologue, ROC2, that also en-
codes a small H2 type RING finger protein of 113 amino acid
residues and interacts with cullins (17). To determine whether
ROC2, like ROC1, alone can also activate UbcH5c in the ab-
sence of a cullin or other cofactors, GST-ROC2 fusion protein
was expressed in bacteria, purified to near homogeneity (Fig.
2A), and incubated with purified CDC34 or Ubc5Hc proteins in
the presence of E1 and 32P-labeled ubiquitin. Similar to ROC1,
recombinant GST-ROC2 efficiently activated UbcH5c, but not
CDC34, to form polyubiquitin chains (Fig. 4C).
All Cullins and APC2 Form Active Ubiquitin Ligases with
ROC and APC11 Proteins—Cullin 1/CDC53 represents a mul-
tigene family, containing six genes in mammalian cells (cullin
1, 2, 3, 4A, 4B, and 5 (Ref. 31)). Different cullins commonly
interact with both ROC1 and ROC2 (17). The findings that
ROC1 and ROC2 proteins can autonomously activate E2 sug-
gest the possibility that all cullins, through their association
with a ROC protein, could contain ubiquitin ligase activity. We
tested this idea by assaying for ubiquitin ligase activity of
individual cullin complexes as well as that of ROC2 complexes.
We have previously characterized six full-length mammalian
cullin cDNAs, CUL1, CUL2, CUL3, mCUL4A, CUL5, and
mAPC2 (17, 27). HA-tagged ROC2 or Myc-tagged cullins were
transfected into 293T cells. Cullin and ROC2 complexes were
immunoprecipitated using either anti-Myc or anti-HA antibod-
ies, respectively, and their associated ubiquitin ligase activities
were assayed using CDC34 or UbcH5c as E2 (Fig. 5, A and C).
Individual cullins were expressed uniformly in 293T cells, and
FIG. 3. RING finger domain of ROC1 is sufficient to activate UbcH5c. A, schematic diagram of wild type and mutant human ROC1
proteins. Filled box represents the RING-H2 finger. The positions of seven conserved Cys and His residues and an Asp residue located at the eighth
zinc binding site are indicated. B, 293T cells were co-transfected with plasmids expressing HA-tagged ROC1 and T7-tagged CUL-1 expression
plasmid as indicated. Cell lysates were precipitated with either anti-HA or anti-T7 antibodies, resolved by SDS-PAGE, and followed by
immunoblotting. C, upper panel, purified GST or GST-ROC1 wild type or mutant fusion proteins were incubated with the same amount of E1,
32P-labeled ubiquitin, and 300 ng of purified UbcH5c. After incubating at 37 °C for 30 min, the reaction was terminated by adding sample buffer
containing SDS (2%) and DTT (0.1 M), boiled for 5 min, and resolved by SDS-PAGE followed by autoradiography. Lower panel, wild type full-length
or mutant ROC1 were fused with GST moiety, expressed in bacteria, and purified using glutathione-agarose. Each purified protein was resolved
by SDS-PAGE followed by Coomassie Blue staining. D, 293T cells were transfected with Myc-tagged ROC1 or in-frame fusion of Myc-tagged
CDK4-ROC1-expressing plasmids. ROC1 or chimerical CDK-ROC1 complexes were recovered with anti-Myc antibody (9E10) and assayed for
ubiquitin ligase activity by incubating with E1, 32P-labeled ubiquitin, and UbcH5c. After incubating at 37 °C for 30 min, the reaction was
terminated by adding sample buffer containing SDS (2%) and DTT (0.1 M), boiled for 5 min, and resolved by SDS-PAGE followed by
autoradiography.
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found to associate with similar amounts of endogenous ROC1
as determined by direct immunoblotting of total cell lysates
and immunoprecipitation Western analysis (Fig. 5B). When
assayed for UBCH5c activation, CUL1 complex exhibited the
highest activity, followed by CUL2, CUL3, CUL5, and CUL4A
complexes.
ROC2 protein displayed preferential association with CUL5,
moderate binding with CUL1 and CUL2, and only low level
interaction with CUL3 and CUL4A (Fig. 5D). These results
suggest that, although ROC1 interacts with different cullins
with similar affinity, ROC2 binding is more cullin-specific.
ROC2-CUL2 complex appeared to activate UBCH5c most effi-
ciently, followed by ROC2-CUL1, CUL3, and CUL5. Consistent
with little association between ROC2 and CUL4A, ROC2 im-
munoprecipitate did not detectably activate UBCH5c when
co-expressed with CUL4A. Somewhat unexpectedly, none of
ROC2-cullin complex exhibited any activity when assayed for
CDC34 activation. Together, these results demonstrate that all
five members of the cullin family (CUL1, CUL2, CUL3,
mCUL4A, CUL5) and ROC2 are assembled in vivo into com-
plexes that contain ubiquitin ligase activity.
CUL1-ROC1, but Not Other Cullin-ROC1 Ligases, Promotes
SKP1- and -TrCP-dependent IB Ubiquitination—Cullin
1/CDC53-associated ubiquitin ligase is targeted to its substrate
FIG. 4. Activation of E2 by ROC1 and ROC2. A, purified GST or GST-ROC1 fusion proteins were incubated with the same amount of E1,
32P-labeled ubiquitin, and 300 ng of various purified E2s. After incubating at 37 °C for 30 min, the reaction was terminated by adding sample buffer
containing SDS (2%) and DTT (0.1 M), boiled for 5 min, and resolved by SDS-PAGE followed by autoradiography. B, CUL1 facilitates ROC1 to
activate CDC34. HA-tagged wild type and mutant ROC1 expression plasmid was co-transfected with Myc3-tagged CUL1 expression plasmid into
293T cells. Anti-HA immunoprecipitates were incubated with the same amount of E1, 32P-labeled ubiquitin, and 300 ng of purified CDC34. After
incubating at 37 °C for 30 min, the reaction was terminated by adding sample buffer containing SDS (2%) and DTT (0.1 M), boiled for 5 min, and
resolved by SDS-PAGE followed by autoradiography. C, purified recombinant GST-ROC2 (Fig. 2A) was incubated with the same amount of E1,
32P-labeled ubiquitin, and 300 ng of purified CDC34 or UbcH5c as indicated. After incubating at 37 °C for 30 min, the reaction was terminated by
adding sample buffer containing SDS (2%) and DTT (0.1 M), boiled for 5 min, and resolved by SDS-PAGE followed by autoradiography.
FIG. 5. ROC1 and ROC2 form active
ubiquitin ligases with all cullins. A
and C, 293T cells were co-transfected
with indicated plasmids. Individual cullin
and ROC2 complexes were recovered with
indicated antibody and assayed for ubiq-
uitin ligase activity by incubating with
E1, 32P-labeled ubiquitin, and either
UbcH5c or Ubc3/CDC34. B and D, total
cell lysates from transfected 293T cells or
aliquots of the same immunoprecipitates
from A and C were resolved by SDS-
PAGE, followed by immunoblotting with
indicated antibodies to determine the lev-
els of expressed cullins and their complex
with ROC1 and ROC2.
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proteins via a complex containing two additional proteins,
SKP1 and an F box protein. In this complex, CUL1/CDC53
simultaneously interacts with SKP1 via an N-terminal domain
(27, 32, 33), with ROC1, and probably through ROC1 with E2
via a C-terminal domain (24). The SKP1 protein, in turn, in-
teracts with the F box protein, which binds to the phosphoryl-
ated substrate protein. We previously found that only CUL1,
but not other cullins, interacts with SKP1 (27), suggesting the
possibility of selective utilization of SKP1 and F box protein in
substrate targeting by CUL1. Detection of ubiquitin ligase
activity of other cullins provides an opportunity to test this
possibility more directly. Individual cullin-ROC1 ubiquitin li-
gases were purified from 293T cells co-transfected with HA-
ROC1 and Myc3-cullins by anti-Myc immunoprecipitation and
assayed using phosphorylated IB as substrate. As previously
reported (17, 20), ROC1 immunocomplexes purified from 293T
cells (Fig. 6A, lane 2), but not the negative control of endog-
enously expressed APC11 (lane 3), exhibited a readily detect-
able level of IB ubiquitin ligase activity. Overexpression of
HA-ROC1 and Myc3-CUL1 substantially increased the IB
ubiquitination activity of the Myc3-CUL1 immunocomplex
(lane 4). In contrast, anti-Myc immunocomplexes derived from
cells co-transfected with HA-ROC1 and other Myc-tagged cul-
lins, including Myc3-CUL2 (lane 5), Myc3-CUL3 (lane 6),
Myc3-mCUL4A (lane 7), and Myc3-CUL5 (lane 8), did not dis-
play detectable IB ubiquitination activity (lanes 5–8). A com-
parable level of ectopic expression of HA-ROC1 and individual
Myc3-cullins was verified by direct immunoblotting with either
HA or Myc antibodies (Fig. 6A, bottom panels).
The F box protein -TrCP targets phosphorylated IB to
CUL1-ROC1 ubiquitin ligase through SKP1 (34). Consistently,
anti-Myc immunocomplexes derived from cells overexpressing
Myc-CUL1, HA-ROC1, SKP1, and -TrCP exhibited signifi-
cantly higher levels of IB ligase activity than those derived
from cells transfected with Myc-CUL1 and HA-ROC1 without
SKP1 and -TrCP (Fig. 6B, compare lane 4 with lane 1). A
double mutation in CUL1, Y42A/M43A, impaired CUL1’s bind-
FIG. 6. SKP1- and -TrCP-dependent in vitro ubiquitination of IB by CUL1, but not other cullins. A, 293T cells were co-transfected
with indicated plasmids. Individual cullin, ROC, or APC11 complexes were recovered with indicated antibody and assayed for ubiquitin ligase
activity using purified IB that was phosphorylated in the presence of [-32P]ATP with IB kinase IKK. Reactions were incubated at 37 °C for
60 min, terminated by adding Laemmli loading buffer, boiled for 4 min, and resolved by SDS-PAGE followed by autoradiography to visualize the
ubiquitinated IB ladders. The level of ectopically expressed HA-ROC1 and Myc3-cullins was examined by direct immunoblotting. Cullins were
expressed as doublets, presumably as the result of covalent NEDD8 modification. B, overexpression of SKP1 and -TrCP enhanced IB
ubiquitination by CUL1, but not other cullins. 293T cells were co-transfected with plasmids expressing indicated proteins. Individual cullin ligases
were recovered by anti-Myc immunoprecipitation and assayed for ubiquitin ligase activity using purified and phosphorylated IB as a substrate.
Note that overexpression of SKP1 and -TrCP substantially enhanced the IB ligase activity of CUL1, but had no detectable effect on IB
ubiquitination by other cullins. C, activation of UbcH5c by ROC1 is not sufficient to ubiquitinate IB. Purified and phosphorylated IB was
incubated with either ROC1-SCF-TrCP or purified ROC1 in the presence of E1, UbcH5c, and ubiquitin (unlabeled). ROC1-SCF-TrCP was prepared
from 293T cells transfected with plasmids expressing HA-ROC1, CUL1, SKP1, and FLAG--TrCP by immunoprecipitation using HA antibody.
Lane 1 contains a negative control of an anti-HA immunocomplex derived from 293T cells transfected with empty pcDNA3 plasmid.
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ing with SKP12 and diminished the IB ubiquitin ligase ac-
tivity of CUL1 (Fig. 6B, lane 2). These results confirm the
specificity of IB ubiquitination by SCF-TrCP and also sug-
gest that SKP1 and/or -TrCP are rate-limiting factors for
IB ligase activity when CUL1 and ROC1 are overexpressed.
Stimulation of the IB ligase activity of CUL1 by overexpres-
sion of SKP1 and -TrCP led us to determine whether other
cullin ligases may be targeted by SKP1 and -TrCP at a lower
efficiency than CUL1 ligase, and whether they may be stimu-
lated to ubiquitinate IB by the overexpression of SKP1/-
TrCP. To test this possibility, Myc-tagged individual cullins
were co-expressed with HA-ROC1, SKP1, and -TrCP, recov-
ered by anti-Myc immunoprecipitation, and assayed for IB
ligase activity in vitro. Under this more sensitive assay condi-
tion, no IB ligase activity was detected for all four cullins
examined (Fig. 6B, lanes 5–9). We conclude that ubiquitin
ligase activity of CUL2, CUL3, mCUL4A, and CUL5, unlike
that of CUL1, cannot be targeted to IB by SKP1 and -TrCP.
In vitro, APC11 is not only capable of activating Ubc4 to form
polyubiquitin chains in the absence of a substrate, it can also
promote E1- and E2-dependent substrate ubiquitination (25,
26). On the other hand, the specific requirement for the N-
terminal SKP1-binding domain of CUL-1 in targeting IB
ubiquitination predicts that activation of E2 by ROC1 to form a
polyubiquitin chain may not necessarily be sufficient to ubiq-
uitinate IB in the absence of CUL1-mediated SCF activity.
To test this prediction, phosphorylated IB was incubated in
vitro with purified recombinant GST-ROC1 in the presence of
E1 and UbcH5c. Under the condition where phosphorylated
IB can be readily ubiquitinated by a ROC1 immunocomplex
derived from cells transfected with ROC1, CUL1, SKP1, and
TrCP (ROC1-SCF-TrCP; Fig. 6C, lane 2), purified recombi-
nant GST-ROC1 cannot promote detectable ubiquitination of
IB (lanes 5 and 6). This result reveals a distinction between
ROC1- and APC11-mediated ubiquitination and differences be-
tween substrates of APC and SCF.
DISCUSSION
The RING Finger Domain of ROC1 Alone Is Sufficient to
Activate E2—Previously, studies have established an essential
function of ROC1 and the integrity of its RING finger for
CUL1-mediated SCF ubiquitin ligase activity (16–20). We
demonstrated in this paper that ROC1 contains two separate
domains: the C-terminal RING finger that is sufficient to acti-
vate E2 UbcH5 ubiquitin-conjugating enzyme to synthesize a
polyubiquitin chain and an N-terminal sequence that is re-
quired for binding with cullins. Deletion of the N-terminal
cullin-binding sequence, leaving virtually only the RING finger
domain, had no detectable effect on the ability of ROC1 to
activate UbcH5c in vitro (Fig. 3). Mutations of metal-binding
Cys and His residues, on the other hand, all disrupt the ligase
activity of ROC1, but only some affect ROC1-CUL1 binding
(e.g. C42S, C45C83S, and H80A (Refs. 29 and 35)). Several
mutations of signature Cys and His residues in ROC1 preserve
its binding with CUL1 (e.g. C53A/C56A and C75A/H77A (Ref.
17)). Taken together, these results indicate that the integrity of
the RING finger is necessary for E2 activation and may also
contribute to, but is not absolutely required for, CUL1 binding.
Because there is little sequence conservation between the dif-
ferent RING fingers, it seems that eight conserved Cys and His
metal binding residues likely contain all necessary information
for interacting with and activating Ubc5.
A biochemical mechanism underlying the RING-E2-medi-
ated polyubiquitination is not clear. One possible function of
RING motif in E2 activation is to facilitate the binding of zinc
ion to E2, as suggested by a recent finding that addition of zinc
ion alone can active Ubc4 to synthesize polyubiquitin (36).
Unlike HECT domain ligases, which forms a thioester bond
intermediate with ubiquitin (7), ubiquitin ligase activity of
ROC1-E2/CDC34 was not inhibited by sulfhydryl-modifying
reagents such as N-ethylmaleimide and iodoacetamide, sug-
gesting that this RING-E2 ligase does not require a reactive
thiol linkage (18, 35). Crystal structural analysis of the c-Cbl
RING finger domain and E2/UbcH7 revealed that the closest
RING domain residue of c-Cbl is 15 Å away from the catalytic
site Cys in Ubc7 (38). Unless conjugation of an ubiquitin with
E2 dramatically changes the structure of RING-E2, the struc-
ture analysis of c-Cbl-Ubc7 suggests that the RING finger does
not directly participate in the catalysis of ubiquitin transfer
from E2 to the substrate and subsequent isopeptide bond for-
mation. We suggest that the RING finger and E2 constitute the
catalytic core of an E3 ubiquitin ligase in which the RING
finger acts as an allosteric activating, rather than catalytic,
subunit to activate E2 to synthesize polyubiquitin chains. Cul-
lin-ROC and APC2-APC11 interactions may represent the
primitive forms of RING family ubiquitin ligases in which the
cullin or APC2 functions to bring together the separate
RING-E2 catalytic core and substrates. During the course of
evolution, many previous RING-interacting proteins might
have incorporated the RING finger as a built-in domain and
become a more efficient ubiquitin ligases.
Using CDC34 as an E2, it was found that ROC1/Hrt1 re-
quires CUL1 for full E3 ligase activity (18). It is somewhat
surprising to see that activation of E2 UbcH5c by ROC1 does
not require a cullin. All ubiquitin-conjugating enzymes contain
a core catalytic domain of 150 amino acids. Based on the
presence and location of additional sequences, E2s have been
divided into four classes: class I consisting almost entirely of
the conserved core domain, and class II, III, and IV containing
additional sequence at the N-terminal, C-terminal, or both
sides of the core domain (39). CDC34, a class III E2, contains a
13-residue insertion between two loops surrounding the ubiq-
uitin-accepting cysteine residue and a 62-residue C-terminal
sequence. Both sequences are absent from Ubc5 and most other
class I ubiquitin-conjugating enzymes, suggesting that neither
sequence is essential for the catalytic function of CDC34. Like
CDC34, yeast Ubc7 also contains a 13-residue insertion be-
tween two loops. Atomic structure analysis indicated that this
insertion alters the surface region of Ubc7, but does not signif-
icantly change its overall folding as compared with other class
I E2s lacking this insertion (40–42). The unique C terminus of
yeast Cdc34 is required for its in vivo function (43). The mo-
lecular basis for the requirement of this C-terminal sequence is
not entirely clear, but it has been speculated to mediate the
dimer formation of Cdc34 or the binding of Cdc34 with Cdc53/
CUL1 and F box protein Cdc4 (43, 44). It will be interesting to
determine whether either of these two sequences in CDC34
hinders its interaction with ROC1 and whether binding with
CUL1 and CUL3 or CDC34 dimerization can release this
inhibition.
Cullin and ROC Constitute a Potentially Large Family of
Ubiquitin Ligases in Vivo—Cullin 1 and ROC1 both represent
multigene families. We present direct biochemical evidence
that, like ROC1, ROC2 also forms an active ubiquitin ligase
with a cullin. We further demonstrate that all five members of
the cullin family we examined constitute ubiquitin ligase ac-
tivity with a ROC protein. Together with our previous report
showing ubiquitin ligase activity of APC2-APC11 (17), these
results demonstrate that ROC and cullin family proteins po-
tentially constitute more than a dozen distinct ligases in vivo.
There exist in vivo a large number of proteins whose levels are2 J. Liu and Y. Xiong, unpublished data.
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known to be regulated by ubiquitin-mediated proteolysis, but
their E3 ubiquitin ligases are yet to be identified. The challenge
now is to identify specific substrates for individual ligases and
elucidate the substrate targeting mechanism. One well charac-
terized mechanism in targeting substrate to a cullin ligase
involves the formation of SCF complex (45, 46). Thus far, how-
ever, the SCF-mediated substrate targeting mechanism ap-
pears to be utilized only by CUL1. In mammalian cells, both
ROC1 and CUL1 complexes contain readily detectable IB
ubiquitin ligase activity that can be further enhanced by the
overexpression of SKP1 and the IB-targeting F box protein
-TrCP (see Ref. 17 and Fig. 6), and abolished by the mutations
in CUL1 that disrupt CUL1-SKP1 binding (Fig. 6B). Under the
same assay conditions, however, IB ubiquitin ligase activity
was not detected in any of the other four cullin immunocom-
plexes purified from the same cell line (Fig. 6). In both mam-
malian (27) and in yeast cells,3 SKP1 does not interact with
other cullins. Because interaction of an F box protein and its
associated substrate with CUL1 is mediated by SKP1 and does
not appear to involve CUL1 itself, these findings indicate that
the initially identified SCF pathway is utilized by perhaps only
a small number of proteins whose ubiquitin-dependent prote-
olysis requires cullin 1 as a part of the E3 ligase. The ubiquiti-
nation of proteins by other cullin-ROC ligases may involve
either a divergent SCF-like pathway such as the von Hippel-
Lindau-elongin C/elongin B complex utilized by the CUL2 li-
gase (37, 47, 48), or a novel mechanism(s).
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